Published in Blood Weekly, February 13th, 2003
The study will evaluate the effect of high dose pulse administration (HDPA) DN-101 (calcitriol) on the anemia and red blood cell transfusion requirements for patients with MDS. Results of previous preclinical and clinical studies have suggested that calcitriol may be useful in treating MDS. Up to 46 patients with low-risk MDS who are red blood cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.